This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Pradaxa® (dabigatran Etexilate Mesylate) Capsules Gains Preferred Formulary Status With AARP®, Nation's Largest Provider Of Medicare Part D Coverage

RIDGEFIELD, Conn., May 19, 2011 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced that Pradaxa ® (dabigatran etexilate mesylate) capsules has received preferred Tier 2 formulary status with all AARP Medicare Part D plans through its pharmacy benefits manager, Prescription Solutions ®.  The AARP plans, which include AARP Medicare Rx and AARP MedicareComplete from Secure Horizons, provide prescription drug access to nearly 6.8 million Americans and represent the largest provider of Medicare Part D coverage in the U.S.  The U.S. Food and Drug Administration (FDA) approved PRADAXA in October 2010 to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF).(1)

More than 25 million Americans are enrolled in a Medicare Part D program, which provides prescription drug coverage for Medicare beneficiaries.  An estimated 2.3 million Americans are living with atrial fibrillation (AFib)(2) and approximately 82 percent are age 65 or older.(2)  A large managed care database study showed that NVAF represents roughly 95 percent of all AFib cases in the U.S.(2)  Atrial fibrillation increases the risk of stroke nearly five times(3) and is associated with up to 15 percent of all strokes in the U.S.(3)

"The addition of PRADAXA to the nation's largest Part D plans helps ensure many more NVAF patients have access to this important medication, which, in a clinical study, has been shown to significantly reduce the risk of stroke compared to warfarin," said Wa'el Hashad, vice president, cardiovascular and metabolic disorders marketing, Boehringer Ingelheim Pharmaceuticals, Inc.  "PRADAXA is now on formulary with AARP, Medco, Express Scripts and several more of the nation's largest managed care providers."

Seven months after FDA approval, PRADAXA is available at the lowest branded co-pay level on formularies that insure more than 45 percent of NVAF patients in the U.S.  This now includes nearly 50 percent of Medicare beneficiaries.  For those patients who may not otherwise be able to afford treatment, BIPI offers patient assistance programs to help provide coverage for the costs of their medications.

1 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,888.35 +168.43 0.95%
S&P 500 2,102.63 +22.22 1.07%
NASDAQ 5,156.3060 +47.64 0.93%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs